Combination Therapies for Breast Cancer

(Morpheus-panBC Trial)

Recruiting at 40 trial locations

Overseen By Reference Study ID Number: CO40115 https://forpatients.roche.com/

Age: 18+

Sex: Any

Trial Phase: Phase 1 & 2

Sponsor: Hoffmann-La Roche

Must not be taking: Immunosuppressants, Antibiotics

Disqualifiers: Autoimmune disease, CNS metastases, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Breakthrough Therapy This drug has been fast-tracked for approval by the FDA given its high promise

Compensation: Varies

Number of Visits: 21

792 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial evaluates the effectiveness of different treatment combinations for individuals with breast cancer that has spread or cannot be removed. It focuses on four groups: those with a specific type of untreated breast cancer, those whose cancer worsened after chemotherapy, and those with certain gene mutations. Suitable candidates include individuals whose breast cancer has spread or cannot be surgically treated and has progressed despite standard treatments. Participants will test various treatment combinations, including Atezolizumab (Tecentriq, an immunotherapy drug), to determine which are safest and most effective. As a Phase 1 trial, the research aims to understand how the treatment works in people, offering participants a chance to contribute to groundbreaking research.

Will I have to stop taking my current medications?

The trial requires that you stop taking certain medications before starting, such as investigational therapies, biologic treatments, and systemic immunosuppressive medications, at least 2 weeks prior to the study. It's best to discuss your specific medications with the study team to see if they are allowed.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that the drugs tested in this trial have varying safety levels based on earlier studies. Atezolizumab, used in other breast cancer treatments, is usually well-tolerated but can cause common side effects like tiredness and nausea, with a risk of more serious issues like infections.

Capecitabine, also used in breast cancer treatment, often causes side effects such as tiredness, diarrhea, and hand-foot syndrome, which involves redness and swelling of the hands and feet.

Gemcitabine, when combined with carboplatin or eribulin, has been effective in breast cancer, with manageable side effects like low blood cell counts and tiredness.

Ipatasertib, when used with other drugs like paclitaxel, generally has manageable side effects, though it may cause diarrhea and nausea.

Nab-Paclitaxel is approved for breast cancer treatment, with common side effects including low blood cell counts and nerve pain.

Sacituzumab govitecan can cause side effects such as diarrhea and low blood cell counts, similar to those of standard chemotherapy.

Selicrelumab is an experimental drug that has shown promise but requires more data to fully understand its safety.

SGN-LIV1A has been tested in other trials and generally shows good tolerability, with side effects similar to other cancer treatments.

Tocilizumab, used for other conditions, carries risks of serious infections but is generally considered safe with careful monitoring.

Overall, these treatments have demonstrated a range of tolerability in various studies. Participants should consider these factors and consult healthcare providers when deciding about joining the trial. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatments?

Researchers are excited about these treatments for breast cancer because they offer innovative combinations that might outperform existing therapies. Unlike standard options, which often focus on single-agent therapies, these investigational treatments combine multiple drugs to target cancer cells more effectively. For example, combining inavolisib with ribociclib and letrozole or fulvestrant brings together different mechanisms that may suppress tumor growth more effectively in hormone receptor-positive breast cancer. Additionally, the combination of inavolisib with trastuzumab deruxtecan targets HER2+/HER2-low breast cancer, potentially offering a new avenue for patients with these specific cancer subtypes. These tailored approaches aim to improve outcomes by addressing the cancer's unique biology.

What evidence suggests that this trial's treatments could be effective for breast cancer?

Studies have shown promising results for several treatment combinations for advanced breast cancer. In this trial, one treatment arm combines inavolisib, ribociclib, and fulvestrant, leading to a median survival of 34 months, a significant improvement over other treatments. Another arm tests inavolisib with trastuzumab deruxtecan, which has effectively slowed cancer progression. Additionally, the trial includes a combination of atezolizumab with chemotherapy drugs like gemcitabine and carboplatin, which previous studies have shown to improve survival rates. These findings suggest that these combinations might effectively treat advanced breast cancer, offering hope for better outcomes. ^{6 7 8 9 10}

Who Is on the Research Team?

Clinical Trials

Principal Investigator

Hoffmann-La Roche

Are You a Good Fit for This Trial?

This trial is for adults with metastatic or locally advanced breast cancer, including those who haven't had systemic therapy for TNBC, have progressed after first-line chemo, or have HR+/HER2- disease with PIK3CA mutation. Participants must be able to take capecitabine and agree to contraception if of childbearing potential. They should not have received certain prior treatments and must meet specific health criteria.

Inclusion Criteria

I haven't had any systemic treatment for my advanced triple-negative breast cancer.

My cancer is HER2 positive or low, and my blood sugar levels are within normal limits.

Your blood sugar levels are within a certain range when fasting and your HbA1c level is not too high.

Exclusion Criteria

I do not meet the exclusion criteria for Stage 1.

You have or had a condition where your immune system attacks your own body, or your immune system doesn't work properly.

I have had cancer spread to the lining of my brain and spinal cord.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment Stage 1

Participants are assigned to one of several treatment arms based on their cohort and receive treatment until unacceptable toxicity or disease progression

Variable, based on individual response

Regular visits as per treatment cycle (21 or 28 days)

Treatment Stage 2

Participants in the 2L CIT-naïve cohort who experience disease progression or loss of clinical benefit during Stage 1 may continue treatment with a different combination

Variable, based on individual response

Follow-up

Participants are monitored for safety and effectiveness after treatment

120 days after last dose

What Are the Treatments Tested in This Trial?

Interventions

• Atezolizumab
• Bevacizumab
• Capecitabine
• Gemcitabine + Carboplatin or Eribulin
• Ipatasertib
• Nab-Paclitaxel
• Sacituzumab Govitecan
• Selicrelumab
• SGN-LIV1A
• Tocilizumab

Trial Overview The study tests various treatment combinations (chemotherapy, targeted drugs like Inavolisib and Ribociclib, immunotherapies such as Atezolizumab) in four different patient cohorts based on their type of breast cancer and previous treatments. It's a two-stage trial where patients may switch treatments if they don't benefit from the initial one.

How Is the Trial Designed?

Group I: Metformin (Metf) + Inavolisib + Fulvestrant ± Palbociclib Experimental Treatment 4 Interventions

Participants with locally advanced or metastatic, HR+, HER2- participants will receive metformin plus inavolisib plus fulvestrant with or without palbociclib until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.

Group II: Inavolisib + Ribociclib (Dose #2) + Letrozole Experimental Treatment 3 Interventions

HR+ participants will receive treatment with inavolisib plus ribociclib plus letrozole until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.

Group III: Inavolisib + Ribociclib (Dose #2) + Fulvestrant Experimental Treatment 3 Interventions

HR+ participants will receive treatment with inavolisib plus ribociclib plus fulvestrant until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.

Group IV: Inavolisib + Ribociclib (Dose #1) + Letrozole Experimental Treatment 3 Interventions

HR+ participants will receive treatment with inavolisib plus ribociclib plus letrozole until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.

Group V: Inavolisib + Ribociclib (Dose #1) + Fulvestrant Experimental Treatment 3 Interventions

HR+ participants will receive treatment with inavolisib plus ribociclib plus fulvestrant until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.

Group VI: Inavolisib + Atirmociclib (Atirmo) + Fulvestrant Experimental Treatment 3 Interventions

Participants will receive inavolisib plus atirmociclib plus fulvestrant until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.

Group VII: Inavolisib + Abemaciclib + Letrozole Experimental Treatment 3 Interventions

HR+ participants will receive treatment with inavolisib plus abemaciclib plus letrozole until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.

Group VIII: Inavolisib + Abemaciclib + Fulvestrant Experimental Treatment 3 Interventions

HR+ participants will receive treatment with inavolisib plus abemaciclib plus fulvestrant until unacceptable toxicity or disease progression determined by the investigator according to RECIST v1.1.

Group IX: Inavolisib (Dose #2) + Trastuzumab Deruxtecan Experimental Treatment 2 Interventions

HER2+/HER2-low participants will receive inavolisib + trastuzumab deruxtecan until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.

Group X: Inavolisib (Dose #1) + Trastuzumab Deruxtecan Experimental Treatment 2 Interventions

HER2+/HER2-low participants will receive inavolisib + trastuzumab deruxtecan until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.

Group XI: Empagliflozin (Empa) + Inavolisib (Inavo) + Fulvestrant (Fulv) ± Palbociclib (Palbo) Experimental Treatment 4 Interventions

Participants with locally advanced or metastatic, HR+, HER2- participants will receive empagliflozin plus inavolisib plus fulvestrant with or without palbociclib until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.

Group XII: Atezolizumab + Selicrelumab + Bevacizumab Experimental Treatment 3 Interventions

2L-CIT-naïve participants will receive doublet combination treatment with atezolizumab plus selicrelumab and bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator. Participants who progressed on treatment may have the option of receiving atezolizumab + chemo, provided they meet the eligibility criteria. Enrollment is closed and participant follow-up is complete.

Group XIII: Atezolizumab + Sacituzumab Govitecan Experimental Treatment 2 Interventions

1L PD-L1-positive participants will receive doublet combination treatment with atezolizumab plus sacituzumab govitecan until unacceptable toxicity or loss of clinical benefit as determined by the investigator. Enrollment is closed.

Group XIV: Atezolizumab + SGN-LIV1A Experimental Treatment 2 Interventions

2L CIT-naïve participants will receive doublet combination treatment with atezolizumab plus SGNLIV1A until unacceptable toxicity or loss of clinical benefit as determined by the investigator. Patients who experience loss of clinical benefit as determined by the investigator or unacceptable toxicity related to SGN-LIV1A will be given the option of receiving Atezolizumab + chemo during Stage 2, provided they meet the eligibility criteria. Enrollment is closed.

Group XV: Atezolizumab + Nab-Paclitaxel + Tocilizumab Experimental Treatment 3 Interventions

1L PD-L1-positive participants will receive combination treatment with atezolizumab plus nab-paclitaxel and tocilizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator. Enrollment is closed.

Group XVI: Atezolizumab + Ipatasertib Experimental Treatment 2 Interventions

2L CIT-naïve participants will receive doublet combination treatment with atezolizumab plus ipatasertib until unacceptable toxicity or loss of clinical benefit as determined by the investigator. Participants who progressed on treatment may have the option of receiving atezolizumab + chemo, provided they meet the eligibility criteria. Enrollment is closed and participant follow-up is complete.

Group XVII: Atezolizumab + Chemo (Gemcitabine + Carboplatin or Eribulin) Experimental Treatment 2 Interventions

2L CIT-naïve participants enrolled in the active comparator arm who experience disease progression per RECIST v1.1 and 2L CIT-naïve participants enrolled in an experimental arm who experience loss of clinical benefit as determined by the investigator may receive doublet combination treatment with atezolizumab plus chemo (gemcitabine + carboplatin or eribulin) until unacceptable toxicity or loss of clinical benefit as determined by the investigator. Enrollment is closed and participant follow-up is complete.

Group XVIII: Capecitabine Active Control 1 Intervention

2L CIT-naïve participants will receive capecitabine until unacceptable toxicity or disease progression per Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1). Participants who progressed on treatment may have the option of receiving atezolizumab along with chemotherapy (chemo) during stage 2, provided they meet the eligibility criteria. Enrollment is closed.

Group XIX: Atezolizumab + Nab-Paclitaxel Active Control 2 Interventions

1L PD-L1-positive participants will receive doublet combination treatment with atezolizumab plus nab-paclitaxel until unacceptable toxicity or loss of clinical benefit as determined by the investigator. Enrollment is closed.

Atezolizumab is already approved in United States, European Union for the following indications:

Approved in United States as Tecentriq for:

• Melanoma
• Hepatocellular carcinoma
• Small cell lung cancer
• Non-small cell lung cancer
• Urothelial carcinoma

Approved in European Union as Tecentriq for:

• Melanoma
• Hepatocellular carcinoma
• Small cell lung cancer
• Non-small cell lung cancer
• Urothelial carcinoma

Who Is Running the Clinical Trial?

Hoffmann-La Roche

Lead Sponsor

Trials

2,482

Recruited

1,107,000+

Headquarters

Basel, Switzerland

Known For

Precision medicine

Top Products

Avastin, Herceptin, Rituxan, Accu-Chek

Dr. Levi Garraway

Hoffmann-La Roche

Chief Medical Officer since 2019

MD from the University of Basel

Dr. Thomas Schinecker

Hoffmann-La Roche

Chief Executive Officer since 2023

PhD in Molecular Biology from New York University

Pfizer

Industry Sponsor

Trials

4,712

Recruited

50,980,000+

Known For

Vaccine Innovations

Top Products

Viagra, Zoloft, Lipitor, Prevnar 13

Albert Bourla

Pfizer

Chief Executive Officer since 2019

PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki

Patrizia Cavazzoni

Pfizer

Chief Medical Officer

MD from McGill University

Seagen Inc.

Industry Sponsor

Trials

212

Recruited

73,800+

Founded

1997

Headquarters

Bothell, USA

Known For

Antibody-Drug Conjugates

Top Products

Adcetris (brentuximab vedotin), Tukysa (tucatinib), Padcev (enfortumab vedotin-ejfv), Tivdak (tisotumab vedotin-tftv)

Dr. Roger Dansey

Seagen Inc.

Chief Medical Officer since 2018

MD from University of Witwatersrand

David R. Epstein

Seagen Inc.

Chief Executive Officer since 2022

BSc in Pharmacy from Rutgers University, MBA from Columbia University

Gilead Sciences

Industry Sponsor

Trials

1,150

Recruited

878,000+

Daniel O'Day

Gilead Sciences

Chief Executive Officer since 2019

MBA from Columbia University

Dietmar Berger

Gilead Sciences

Chief Medical Officer

MD and PhD from Albert-Ludwigs University School of Medicine

Published Research Related to This Trial

Combination therapies using paclitaxel with other antineoplastic agents show promise for treating metastatic breast cancer, but optimal dosing and scheduling remain unclear, which complicates their development.

Unexpected toxic interactions between paclitaxel and other drugs have been observed, highlighting the need for careful evaluation of combination therapies in clinical trials before they are used outside of research settings.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review. Holmes, FA.[2015]

Capecitabine is a well-tolerated treatment for metastatic breast cancer, showing minimal side effects like myelosuppression and hair loss, which makes it a promising option for combination therapies with other anticancer drugs.

Ongoing phase II/III trials are investigating the use of capecitabine in early breast cancer treatment, and preliminary results indicate that it may provide significant benefits when used as part of adjuvant and neoadjuvant therapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Future options with capecitabine (Xeloda) in (neo)adjuvant treatment of breast cancer. Fumoleau, P., Cameron, D.[2019]

In the IMpassion131 trial involving 651 patients with advanced triple-negative breast cancer, adding atezolizumab to paclitaxel did not improve progression-free survival (PFS) or overall survival (OS) compared to paclitaxel alone, indicating that this combination may not provide the expected benefits in treatment outcomes.

While the addition of atezolizumab showed a higher unconfirmed overall response rate and longer duration of response in the PD-L1-positive population, the overall survival results were similar between the two treatment groups, suggesting that the combination therapy does not significantly enhance long-term survival.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Miles, D., Gligorov, J., André, F., et al.[2021]

In a study involving 55 women with metastatic breast cancer, the combination of weekly paclitaxel and capecitabine resulted in a 55% objective response rate, indicating significant antitumor activity as a first-line treatment.

The treatment was generally tolerable, with a clinical benefit rate of 65% and a median duration of response of 10 months, although some patients experienced notable side effects like hand-foot skin reactions and neutropenia.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer. Blum, JL., Dees, EC., Chacko, A., et al.[2015]

In a study involving 58 patients with recurrent HER2-negative breast cancer, eribulin showed a median progression-free survival (PFS) of 6.6 months compared to 4.2 months for treatment of physician's choice (TPC), suggesting a potential benefit in delaying disease progression.

Although eribulin demonstrated improved median time to treatment failure (TTF) of 6.0 months versus 3.6 months for TPC, these differences were not statistically significant, indicating that further studies are necessary to confirm the efficacy of eribulin in this setting.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19). Aogi, K., Watanabe, K., Kitada, M., et al.[2022]

This phase III study will evaluate the non-inferiority of eribulin, a non-taxane microtubule inhibitor, compared to taxanes in combination with trastuzumab and pertuzumab for treating HER2-positive metastatic breast cancer in 480 Japanese women.

The primary goal is to assess progression-free survival, with the potential for eribulin to become a safer alternative to taxanes if proven equally effective, addressing safety concerns associated with taxane-induced toxicities.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD). Yamashita, T., Masuda, N., Saji, S., et al.[2021]

Atezolizumab, combined with nab-paclitaxel, significantly improved progression-free survival in patients with advanced triple-negative breast cancer (TNBC) compared to placebo, based on the phase III IMpassion130 trial involving patients with unresectable locally advanced or metastatic TNBC.

While the combination therapy showed a tolerable safety profile, with common side effects like neutropenia and immune-related adverse events, it did not significantly affect health-related quality of life for patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer. Kang, C., Syed, YY.[2020]

Capecitabine, an oral chemotherapy drug, has shown improved disease-free and overall survival when combined with docetaxel in advanced breast cancer, leading to further exploration of its combinations with other agents.

The combination of capecitabine with docetaxel and epirubicin (TEX) has demonstrated promising results and manageable toxicity, and is currently being evaluated in phase III trials for advanced disease.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

New directions with capecitabine combinations in advanced breast cancer. Budman, DR.[2015]

In a study of 40 patients with HER2-positive metastatic breast cancer, the combination of trastuzumab, paclitaxel, and capecitabine resulted in a high overall response rate of 81.1%, with 24.3% achieving complete responses and 56.8% partial responses.

The treatment was well-tolerated, with manageable grade 3 adverse events, indicating that this combination therapy is both effective and safe for first-line treatment in this patient population.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer. Tonyali, O., Benekli, M., Berk, V., et al.[2021]

In a study of 29 patients with HER2-positive operable breast cancer, the combination of nab-paclitaxel and trastuzumab followed by FEC resulted in a high pathological complete response (pCR) rate of 74.0%, indicating strong efficacy in the neoadjuvant chemotherapy setting.

The treatment was generally well tolerated, with sensory neuropathy being the most common side effect; however, severe grade 3 neuropathy occurred in only 3.4% of patients, suggesting a favorable safety profile.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Trastuzumab Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide for HER2-positive Operable Breast Cancer: A Multicenter Phase II Trial. Tokunaga, S., Takashima, T., Kashiwagi, S., et al.[2019]

Atezolizumab, when used with nab-paclitaxel for treating triple negative breast cancer, can cause rare side effects like autoimmune hemolytic anemia, as seen in a case study of a 59-year-old female patient.

The patient's hemolytic anemia was effectively managed with a high-dose prednisone taper, allowing her to continue her cancer treatment without further complications through multiple cycles.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Atezolizumab-induced hemolytic anemia - A case report. Younce, CM., Lawton, JM., Patel, DR.[2021]

Citations

1. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC7808100/

Phase II study of eribulin in combination with gemcitabine for ... Highlights. Eribulin plus gemcitabine showed a remarkable best ORR of 37.3% and a clinical benefit rate of 48.8%. The most common grade 3/4 toxicities were ...

2. clinicaltrials.gov clinicaltrials.gov/study/NCT03424005

NCT03424005 | A Study Evaluating the Efficacy and Safety ... This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced ...

3. annalsofoncology.org annalsofoncology.org/article/S0923-7534(24)00107-8/fulltext

IMpassion132 double-blind randomised phase III trial ... One-year survival rates were 48% (95% CI 40% to 55%) in the placebo arm versus 50% (95% CI 43% to 58%) in the atezolizumab arm; corresponding 18 ...

4. bmccancer.biomedcentral.com bmccancer.biomedcentral.com/articles/10.1186/s12885-024-12953-9

Eribulin plus carboplatin combination for HER2-negative ... ErCb demonstrated favorable efficacy and tolerability in patients with heavily pre-treated mBC, especially TNBC. The findings of the current ...

5. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC10722391/

The TBCRC 043 Phase 2 Randomized Clinical Trial - PMC In this randomized clinical trial including 106 patients, combining atezolizumab with carboplatin significantly improved progression-free and overall survival ...

6. accessdata.fda.gov accessdata.fda.gov/drugsatfda_docs/label/2019/761034s021lbl.pdf

Atezolizumab - accessdata.fda.gov The safety of TECENTRIQ was evaluated in ... The most common side effects of TECENTRIQ when used in triple-negative breast cancer with paclitaxel protein-.

7. tecentriq.global tecentriq.global/home/indication/triple-negative-breast-cancer.html

Triple-negative breast cancer - tecentriq See TECENTRIQ indication and review efficacy and safety data for TECENTRIQ + nab-paclitaxel from the Phase 3 IMpassion130 trial in patients with advanced ...

8. ema.europa.eu ema.europa.eu/en/medicines/human/EPAR/tecentriq

Tecentriq | European Medicines Agency (EMA) A study of 902 patients with a type of breast cancer known as triple-negative breast cancer looked at the effect of combining Tecentriq with nab-paclitaxel.

9. tecentriq-hcp.com tecentriq-hcp.com/

TECENTRIQ® (atezolizumab) HCP | Efficacy, Safety, PI & MOA Based on its mechanism of action, TECENTRIQ can cause fetal harm when administered to a pregnant woman. There are no available data on the use of TECENTRIQ in ...

10. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC12283416/

Peri-operative atezolizumab in early-stage triple-negative ... These data show that adding atezolizumab to chemotherapy for stage II/III TNBC is associated with favorable long-term outcomes, and ctDNA ...